WILLIAM G WIERDA to Immunotherapy
This is a "connection" page, showing publications WILLIAM G WIERDA has written about Immunotherapy.
Connection Strength
1.463
-
Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy. Blood. 2019 11 28; 134(22):1951-1959.
Score: 0.261
-
Evolving Strategies in First-Line Chronic Lymphocytic Leukemia: Is There a Role for Chemoimmunotherapy? J Natl Compr Canc Netw. 2019 11; 17(11.5):1408-1410.
Score: 0.260
-
Investigational immunotherapeutics for B-cell malignancies. J Clin Oncol. 2010 Feb 10; 28(5):884-92.
Score: 0.132
-
Novel immune-based treatment strategies for chronic lymphocytic leukemia. J Clin Oncol. 2005 Sep 10; 23(26):6325-32.
Score: 0.098
-
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology J Natl Compr Canc Netw. 2024 04; 22(3):175-204.
Score: 0.088
-
Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer. Nat Rev Clin Oncol. 2021 07; 18(7):435-453.
Score: 0.071
-
Adverse Events of Novel Therapies for Hematologic Malignancies: What Emergency Physicians Should?Know. Ann Emerg Med. 2020 02; 75(2):264-286.
Score: 0.065
-
Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies. Leukemia. 2018 11; 32(11):2388-2398.
Score: 0.058
-
Consolidation treatment with lenalidomide following front-line or salvage chemoimmunotherapy in chronic lymphocytic leukemia. Haematologica. 2017 12; 102(12):e494-e496.
Score: 0.056
-
Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL. Blood. 2016 Jan 21; 127(3):279-86.
Score: 0.049
-
Progress in novel cellular therapy options for chronic lymphocytic leukemia: the M D Anderson perspective. Clin Lymphoma Myeloma Leuk. 2014 Sep; 14 Suppl:S18-22.
Score: 0.045
-
Immunotherapy for chronic lymphocytic leukemia in the era of BTK inhibitors. Leukemia. 2014 Mar; 28(3):507-17.
Score: 0.043
-
Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: analysis of persistent and new-onset cytopenia. Cancer. 2013 Nov 01; 119(21):3805-11.
Score: 0.042
-
Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. Blood. 2011 Jun 16; 117(24):6450-8.
Score: 0.036
-
Chronic lymphocytic leukemia: new concepts for future therapy. Clin Lymphoma Myeloma Leuk. 2010 Oct; 10(5):369-78.
Score: 0.035
-
Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment. J Clin Oncol. 2009 Apr 01; 27(10):1637-43.
Score: 0.031
-
Richter's transformation in chronic lymphocytic leukemia. Curr Hematol Malig Rep. 2007 Oct; 2(4):265-71.
Score: 0.028
-
Chronic lymphocytic leukaemia. Lancet. 2024 Aug 17; 404(10453):694-706.
Score: 0.023
-
ZNF683 marks a CD8+ T?cell population associated with anti-tumor immunity following anti-PD-1 therapy for Richter syndrome. Cancer Cell. 2023 10 09; 41(10):1803-1816.e8.
Score: 0.021
-
Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens. Blood. 2009 Apr 02; 113(14):3168-71.
Score: 0.008
-
Multiple-dose granulocyte-macrophage-colony-stimulating factor plus 23-valent polysaccharide pneumococcal vaccine in patients with chronic lymphocytic leukemia: a prospective, randomized trial of safety and immunogenicity. Cancer. 2008 Jul 15; 113(2):383-7.
Score: 0.007
-
Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 2006 Apr 01; 106(7):1569-80.
Score: 0.006